Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-Current Debt (2024 - 2025)

Historic Non-Current Debt for Karyopharm Therapeutics (KPTI) over the last 2 years, with Q4 2025 value amounting to $94.8 million.

  • Karyopharm Therapeutics' Non-Current Debt rose 20.3% to $94.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $94.8 million, marking a year-over-year increase of 20.3%. This contributed to the annual value of $94.8 million for FY2025, which is 20.3% up from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Non-Current Debt stood at $94.8 million, which was up 20.3% from $83.9 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Non-Current Debt peaked at $95.2 million during Q1 2025, and registered a low of $83.9 million during Q3 2025.